It’s a very rewarding trading day for Aimmune Therapeutics Inc (NASDAQ:AIMT) investors with shares up over 30%, making the stock Wall Street’s bull of the day. The reason? The allergy medicine maker benefited from the news that its competitor DBV Technologies SA – ADR (NASDAQ:DBVT) reported disappointing late-stage clinical trial results for its experimental treatment, Viaskin Peanut, a patch designed to enhance protection of peanut allergic children.
Aimmune is developing AR101 to enable the convenient dosing of consistent amounts of peanut protein with well-defined concentrations of peanut allergens. If approved, it will be available in a range of accurately quantified dosages from 0.5 milligrams up to 300 milligrams to support the company’s approach, from initiation to maintenance.
The company has successfully completed Phase 2 studies of AR101 for the treatment of peanut allergy and is currently enrolling patients for our Phase 3 PALISADE (Peanut ALlergy Oral Immunotherapy Study of AR101 for DEsensitization in Children and Adults) trial.
The FDA granted AR101 Fast Track Designation status, followed by Breakthrough Therapy Designation status, for its potential to treat a serious condition and fill an unmet medical need.
Corporate presentation October 2017
On the ratings front, Aimmune stock has been the subject of a number of recent research reports. In a report released today, Credit Suisse analyst Vamil Divan reiterated a Buy rating on AIMT, with a price target of $45, which implies an upside of 27% from current levels. On October 20, Piper Jaffray’s Charles Duncan reiterated a Buy rating on the stock and has a price target of $38.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vamil Divan and Charles Duncan have a yearly average loss of 0.8% and a return of 3.6% respectively. Divan has a success rate of 48% and is ranked #3706 out of 4703 analysts, while Duncan has a success rate of 48% and is ranked #1460.
Aimmune is a clinical-stage biopharmaceutical company. It engages in the research and development of desensitization treatments for peanut and other food allergies. The company’s portfolio includes the characterized oral desensitization immunotherapy system. Its pipeline consists of AR101, program 2 and 3.